ATE444077T1 - Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen - Google Patents

Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen

Info

Publication number
ATE444077T1
ATE444077T1 AT01945716T AT01945716T ATE444077T1 AT E444077 T1 ATE444077 T1 AT E444077T1 AT 01945716 T AT01945716 T AT 01945716T AT 01945716 T AT01945716 T AT 01945716T AT E444077 T1 ATE444077 T1 AT E444077T1
Authority
AT
Austria
Prior art keywords
pharmaceutical
diseases
demyelination
prevention
treatment
Prior art date
Application number
AT01945716T
Other languages
English (en)
Inventor
Hiroaki Asou
Makoto Sugawa
Original Assignee
Tokyo Metropolitan Inst Of Ger
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Metropolitan Inst Of Ger, Chugai Pharmaceutical Co Ltd filed Critical Tokyo Metropolitan Inst Of Ger
Application granted granted Critical
Publication of ATE444077T1 publication Critical patent/ATE444077T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01945716T 2000-06-30 2001-06-29 Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen ATE444077T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000199421 2000-06-30
PCT/JP2001/005641 WO2002002135A1 (fr) 2000-06-30 2001-06-29 Preventifs et remedes contre des maladies associees a la demyelinisation

Publications (1)

Publication Number Publication Date
ATE444077T1 true ATE444077T1 (de) 2009-10-15

Family

ID=18697441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945716T ATE444077T1 (de) 2000-06-30 2001-06-29 Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen

Country Status (7)

Country Link
US (1) US8039253B2 (de)
EP (1) EP1295604B1 (de)
JP (1) JP5053499B2 (de)
AT (1) ATE444077T1 (de)
AU (1) AU2001267882A1 (de)
DE (1) DE60140054D1 (de)
WO (1) WO2002002135A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8522873B2 (en) 2005-09-09 2013-09-03 Halliburton Energy Services, Inc. Spacer fluids containing cement kiln dust and methods of use
US8327939B2 (en) 2005-09-09 2012-12-11 Halliburton Energy Services, Inc. Settable compositions comprising cement kiln dust and rice husk ash and methods of use
US8672028B2 (en) 2010-12-21 2014-03-18 Halliburton Energy Services, Inc. Settable compositions comprising interground perlite and hydraulic cement
US8297357B2 (en) * 2005-09-09 2012-10-30 Halliburton Energy Services Inc. Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and methods of use
US9150773B2 (en) 2005-09-09 2015-10-06 Halliburton Energy Services, Inc. Compositions comprising kiln dust and wollastonite and methods of use in subterranean formations
US8555967B2 (en) 2005-09-09 2013-10-15 Halliburton Energy Services, Inc. Methods and systems for evaluating a boundary between a consolidating spacer fluid and a cement composition
US8281859B2 (en) 2005-09-09 2012-10-09 Halliburton Energy Services Inc. Methods and compositions comprising cement kiln dust having an altered particle size
US8609595B2 (en) 2005-09-09 2013-12-17 Halliburton Energy Services, Inc. Methods for determining reactive index for cement kiln dust, associated compositions, and methods of use
US8333240B2 (en) 2005-09-09 2012-12-18 Halliburton Energy Services, Inc. Reduced carbon footprint settable compositions for use in subterranean formations
US9676989B2 (en) 2005-09-09 2017-06-13 Halliburton Energy Services, Inc. Sealant compositions comprising cement kiln dust and tire-rubber particles and method of use
US9006155B2 (en) 2005-09-09 2015-04-14 Halliburton Energy Services, Inc. Placing a fluid comprising kiln dust in a wellbore through a bottom hole assembly
US9023150B2 (en) 2005-09-09 2015-05-05 Halliburton Energy Services, Inc. Acid-soluble cement compositions comprising cement kiln dust and/or a natural pozzolan and methods of use
US8403045B2 (en) 2005-09-09 2013-03-26 Halliburton Energy Services, Inc. Settable compositions comprising unexpanded perlite and methods of cementing in subterranean formations
US8505630B2 (en) 2005-09-09 2013-08-13 Halliburton Energy Services, Inc. Consolidating spacer fluids and methods of use
US8307899B2 (en) 2005-09-09 2012-11-13 Halliburton Energy Services, Inc. Methods of plugging and abandoning a well using compositions comprising cement kiln dust and pumicite
US8950486B2 (en) 2005-09-09 2015-02-10 Halliburton Energy Services, Inc. Acid-soluble cement compositions comprising cement kiln dust and methods of use
US9051505B2 (en) 2005-09-09 2015-06-09 Halliburton Energy Services, Inc. Placing a fluid comprising kiln dust in a wellbore through a bottom hole assembly
US9809737B2 (en) 2005-09-09 2017-11-07 Halliburton Energy Services, Inc. Compositions containing kiln dust and/or biowaste ash and methods of use
US8505629B2 (en) 2005-09-09 2013-08-13 Halliburton Energy Services, Inc. Foamed spacer fluids containing cement kiln dust and methods of use
DE102006004008A1 (de) * 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
WO2008023725A1 (fr) 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Agent préventif et/ou thérapeutique pour une neuropathie périphérique
WO2009010107A1 (en) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
WO2010092419A1 (en) * 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
WO2016069950A2 (en) * 2014-10-29 2016-05-06 University Of Utah Research Foundation Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1)
CN115501234B (zh) * 2021-08-02 2023-08-08 中山大学·深圳 化合物在制备防治脱髓鞘疾病药物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
JP2003520194A (ja) * 1999-04-13 2003-07-02 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 末梢投与したエリスロポエチンによる興奮組織機能のモジュレート
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
JP2001010972A (ja) * 1999-06-30 2001-01-16 Masahiro Sakanaka プロサポシン関連ペプチドからなる細胞保護剤

Also Published As

Publication number Publication date
DE60140054D1 (de) 2009-11-12
EP1295604A4 (de) 2005-04-27
EP1295604A1 (de) 2003-03-26
WO2002002135A1 (fr) 2002-01-10
AU2001267882A1 (en) 2002-01-14
US8039253B2 (en) 2011-10-18
JP5053499B2 (ja) 2012-10-17
EP1295604B1 (de) 2009-09-30
US20050032682A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE444077T1 (de) Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
PT1040830E (pt) Medicamento para doencas neurodegenerativas
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
EP0722737A4 (de) Arznei gegen die störung des cranialen nervan
IL159299A0 (en) Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
BR0315008A (pt) Compostos neurologicamente ativos
CY1112126T1 (el) Χρηση toy vegf 165 και των ομολογων για την αγωγη διαταραχων των νευρωνων
ATE252389T1 (de) Ein arzneimittel zur behandlung von fettleibigkeit und verbesserung des lipidmetabolismus
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
BR0009296A (pt) Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto
WO2003068147A3 (en) Treatments for neurotoxicity in alzheimer’s disease
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
ES2179166T3 (es) Composiciones para la prevencion y tratamiento de trastornos urogenitales, que contienen bismuto y uno o mas agentes antimicrobianos.
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
ATE476188T1 (de) Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
WO2023107653A3 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
DE60008111D1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties